Oruka Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.29) Per Share, Leerink Partnrs Forecasts (NASDAQ:ORKA)

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Investment analysts at Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for shares of Oruka Therapeutics in a report issued on Tuesday, September 17th. Leerink Partnrs analyst D. Risinger expects that the company will earn ($0.29) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.03) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.46) EPS and FY2026 earnings at ($1.92) EPS.

ORKA has been the topic of a number of other research reports. Leerink Partners initiated coverage on Oruka Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $44.00 price objective on the stock. Wedbush assumed coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. TD Cowen assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating for the company. Finally, Lifesci Capital started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective on the stock. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $41.25.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $25.00 on Thursday. Oruka Therapeutics has a fifty-two week low of $18.72 and a fifty-two week high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.